Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results

British Journal of Haematology

Volumn 166, Issue 1, 2014, Pages 109-117

  Jackson, Graham H ^a   Morgan, Gareth J ^b   Davies, Faith E ^b   Wu, Ping ^b   Gregory, Walter M ^c   Bell, Sue E ^c   Szubert, Alexander J ^c   Navarro Coy, Nuria ^c   Drayson, Mark T ^d   Owen, Roger G ^e   Feyler, Sylvia ^f   Ashcroft, Andrew J ^g   Ross, Fiona M ^h   Byrne, Jennifer ⁱ   Roddie, Huw ^j   Rudin, Claudius ^k   Boyd, Kevin D ^b   Osborne, Wendy L ^l   Cook, Gordon ^e   Child, J Anthony ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST   (United Kingdom)

^g MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^j WESTERN GENERAL HOSPITAL   (United Kingdom)

^k ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^l FREEMAN HOSPITAL   (United Kingdom)

more..

Author keywords

Clodronate; Myeloma; Osteonecrosis; Renal injury; Zolendronic acid

Indexed keywords

CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

CLODRONATE; MYELOMA; OSTEONECROSIS; RENAL INJURY; ZOLENDRONIC ACID;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; ENGLAND; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOLYSIS;

EID: 84902314766     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12861     Document Type: Article

References (21)

1. Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L.A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., Terpos, E. & Dimopoulos, M.A. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology, 23, 8580-8587.
2. Bird, J.M., Owen, R.G., D'Sa, S., Snowden, J., Pratt, G., Ashcroft, A., Yong, K., Cook, G., Feyler, S., Davies, F., Morgan, G., Cavenagh, J., Low, E. & Behrens, J. (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 154, 32-75.
3. Dimopoulos, M.A., Kastritis, E., Anagnostopoulos, A., Melakopoulos, I., Gika, D., Moulopoulos, L., Bamia, C., Terpos, E., Tsionos, K. & Bamias, A. (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica, 91, 968-971.
4. Dimopoulos, M.A., Kastritis, E., Bamia, C., Melakopoulos, I., Gika, D., Roussou, M., Migkou, M., Elefttherakis-Papaikovou, E., Christoulas, D., Terpos, E. & Bamias, A. (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology, 20, 117-120.
5. Durie, B.G. (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clinic Proceedings, 82, 516-517; author reply 517-518.
6. Durie, B.G., Katz, M. & Crowley, J. (2005) Osteonecrosis of the jaw and bisphosphonates. New England Journal of Medicine, 353, 99-100.
7. Gimsing, P., Carlson, K., Turesson, I., Fayers, P., Waage, A., Vangsted, A., Mylin, A., Gluud, C., Juliusson, G., Gregersen, H., Hjorth-Hansen, H., Nesthus, I., Dahl, I., Westin, J., Nielsen, J., Knudsen, L., Ahlberg, L., Hjorth, M., Abilgaard, N., Anderson, N., Linder, O. & Wisloff, F. (2010) Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. The Lancet Oncology, 11, 973-982.
8. Henry, D.H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scaqliotti, G.V., Sleeboom, H., Spencer, A., Vadhan-Rai, S., Von Moos, R., Willenbacher, W., Woll, P.J., Wang, J., Jiang, Q., Jun, S., Dansey, R. & Yeh, H. (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology, 29, 1125-1132.
9. Kyle, R.A. & Rajkumar, S.V. (2009) Treatment of multiple myeloma: a comprehensive review. Clinical Lymphoma & Myeloma, 9, 278-288.
10. Kyle, R.A., Yee, G.C., Somerfield, M.R., Flynn, P.J., Halabi, S., Jagannath, S., Orlowski, R.Z., Roodman, D.G., Twilde, P. & Anderson, K. (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology, 25, 2464-2472.
11. Lacy, M.Q., Dispenzieri, A., Gertz, M.A., Greipp, P.R., Gollbach, K.L., Hayman, S.R., Kumar, S., Lust, J.A., Raikumar, S.V., Russell, S.J., Witzig, T.E., Zeldenrust, S.R., Dingli, D., Bergsagel, P.L., Fonseca, R., Reeder, C.B., Stewart, A.K., Roy, V., Dalton, R.J., Carr, A.B., Kademani, D., Keller, E.E., Viozzi, C.F. & Kyle, R.A. (2006) Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic Proceedings, 81, 1047-1053.
12. Mehrotra, B., Fantasia, J. & Ruggiero, S.L. (2008) Outcomes of bisphosphonate-related osteonecrosis of the jaw-importance of staging and management guidelines: a large single institutional update. Journal of Clinical Oncology, 26, Abstract 20526.
13. Montefusco, V., Gay, F., Spina, F., Miceli, R., Maniezzo, M., Ambrosini, M.T., Farina, L., Piva, S., Palumbo, A., Boccadoro, M. & Corradini, P. (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukaemia Lymphoma, 49, 2156-2162.
14. Morgan, G.J., Davies, F.E., Gregory, W.M., Cocks, K., Bell, S., Szubert, J., Navarro-Coy, N., Drayson, M., Owen, R., Feyler, S., Ashcroft, A.J., Ross, F., Byrne, J., Roddie, H., Rudin, C., Cook, G., Jackson, G.H. & Child, J.A. (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet, 376, 1989-1999.
15. Morgan, G.J., Child, J.A., Gregory, W.M., Szubert, A.J., Cocks, K., Bell, S., Navarro-Coy, N., Drayson, M., Owen, R., Feyler, S., Ashcroft, A.J., Ross, F., Byrne, J., Roddie, H., Rudin, C., Cook, G., Jackson, G.H., Wu, P. & Davies, F. (2011a) Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. The Lancet Oncology, 12, 743-752.
16. Morgan, G.J., Davies, F.E., Gregory, W.M., Bell, S.E., Szubert, A.J., Brown, J.M., Coy, N.N., Cook, G., Russell, N.H., Rudin, C., Roddie, H., Drayson, M.T., Owen, R.G., Ross, F.M., Jackson, G.H. & Child, J.A. (2011b) MRC Myeloma IX, 6-year median follow-up (FU) highlights the importance of long-term FU in myeloma clinical trials and differential effects of thalidomide in high- and low-risk disease. Blood, 118: t 993.
17. Morgan, G.J., Davies, F.E., Gregory, W.M., Szubert, A., Bell, S., Drayson, M., Owen, R., Ashcroft, A.J., Jackson, G.H. & Child, J.A. (2012) Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: MRC Myeloma IX trial. Blood, 119, 5374-5383.
18. Terpos, E., Sezer, O., Croucher, P.I., Garcia-Sanz, R., Boccadoro, M., San Miguel, J., Ashcroft, J., Blade, J., Cavo, M., Delforge, M., Dimopoulos, M.-A., Facon, T., Macro, M., Waage, A. & Sonneveld, P. (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology, 20, 1303-1317.
19. Terpos, E., Morgan, G., Dimopoulos, M., Drake, M., Lentzsch, S., Raje, N., Sezer, O., Garcia Sanz, R., Shimizu, K., Turesson, I., Reiman, T., Jurczyszyn, A., Merlini, G., Spencer, A., Leleu, X., Cavo, M., Munshi, N., Rajkumar, S., Durie, B. & Roodman, G.D. (2013) International Working Group recommendations for the treatment of multiple myeloma related bone disease. Journal of Clinical Oncology, 31, 2347-2357.
20. Weitzman, R., Sauter, N., Eriksen, E.F., Tarassoff, P.G., Lacema, L.V., Dias, R., Altmever, A., Csermak-Renner, K., McGrath, L., Lantwicki, L. & Hohneker, J.A. (2007) Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Critical Reviews in Oncology/Hematology, 62, 148-152.
21. Zervas, K., Verrou, E., Teleioudis, Z., Vahtsevanos, K., Banti, A., Mihou, D., Krikelis, D. & Terpos, E. (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. British Journal of Haematology, 134, 620-623.